NIH Renews Genomatix License
News Oct 10, 2005
Genomatix Software GmbH has renewed its license agreement with the NCI (National Cancer Institute) under which NIH (National Institutes of Health) intramural researchers nation wide do have full access to the Genomatix suite of software tools and databases. The new license includes Genomatix' ChipInspector which will be released later this year. ChipInspector, as well as all the other Genomatix products, recently have been awarded with the "Gene Chip Compatible" status from Affymetrix Inc. ChipInspector allows for single probe chip analysis, including latest up to date genome information from Genomatix’ ElDorado genomic annotation engine.
Applying the full Genomatix chip analysis pipeline to a researcher's microarray results raw data strongly enhances the identification of significantly changed transcripts, generates the full biological network of involved genes, and allows for functional analysis of the sub-networks most relevant for the experimental set-up. Downstream analysis looks for common promoter organization being responsible for co-regulation of involved genes. Large scale genomic database scanning with such organizational patterns identifies additional genes belonging to a common regulatory environment.
Dr. Martin Seifert, Vice President of Microarray Business at Genomatix stated: "I am very happy that the renowned experts from the NIH will be among the first non-Genomatix scientists who will have access to ChipInspector and our entire chip analysis pipeline. I am very keen to see high level scientific results and expect a boost of new publications citing our tools"
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.